The exercise period for Amniotics’ warrants of series TO1 commences today
May 5, 2022
Amniotics AB (publ) (“Amniotics” or the “Company”) conducted a unit issue of shares and warrants of series TO1 (the “warrants”) in connection with the listing on Nasdaq First North Growth Market on July 6, 2021. The exercise period for the warrants commences today, May 5, 2022, and runs up to and including May 19, 2022. One (1) warrant entitles the holder to subscribe for one (1) new share in Amniotics. The subscription price per share that is subscribed for through exercising the warrants has, in accordance with the terms and conditions for the warrants, been set to SEK 23.50. If all warrants are exercised, Amniotics will receive approximately SEK 34.4 million before issuing costs.
Summary of instructions and important dates
Holders of warrants who wish to exercise these to subscribe for shares shall give notice regarding such exercise well before May 19, 2022. Warrants that have not been exercised on or before May 19, 2022, expire without value. Holders who do not wish to exercise their warrants may sell them. Trading with warrants is ongoing up to and including May 17, 2022.
Detailed information and instructions for subscription
Exercise of nominee-registered warrants
Holders of warrants who have their holdings nominee-registered (holdings in securities custody services, investment savings accounts (ISK) or endowment insurances) must notify the exercise of warrants by contacting their respective nominee and follow the nominee's instructions regarding subscription and payment. This should take place well before May 19, 2022, as different nominees have different processing times.
Exercise of directly registered warrants
Holders of warrants who have their holdings directly registered (holdings on a VP account) must notify the exercise of warrants by completing and submitting an application form for the exercise, so that the application form is received by the issuing agent, Nordic Issuing, no later than May 19, 2022.
The application form is available on the Company's, the issuing agent's and Redeye AB's respective websites (www.amniotics.com, www.nordic-issuing.se, www.redeye.se). Please note that payment for the new shares must be received by Nordic Issuing no later than May 19, 2022, in accordance with the instructions on the application form.
Trading in TO1
Holders who do not wish to exercise their warrants may sell them on Nasdaq First North Growth Market. The warrants are traded up to and including May 17, 2022, under the short name TO1 and with ISIN code SE0016101471. Warrants that are not exercised on May 19, 2022, at the latest or sold on May 17, 2022, at the latest will expire without value.
Outcome and delivery of new shares
The outcome of the exercise of warrants will be published via a press release on or around May 23, 2022. Shares that have been subscribed and paid for may be registered on the subscriber's securities depository as interim shares (IA) until registration of the issue has been completed with the Swedish Companies Registration Office, whereupon the interim shares automatically will be converted into ordinary shares in Amniotics.
Number of warrants and possible proceeds
The number of warrants amounts to 1,463,415. Upon full exercise of all warrants, Amniotics will receive approximately SEK 34.4 million before issuing costs. Upon full exercise of all warrants, the number of shares in Amniotics will increase with 1,463,415 shares to 17,529,745 shares and the share capital will increase with SEK 79,154.86 to SEK 948,168.81. This entails a dilution of approximately 8.35 percent based on the number of shares in Amniotics after full exercise of all warrants.
Complete terms and conditions for the warrants
Complete terms and conditions for the warrants are available on the Company’s website, www.amniotics.com.
Redeye AB acts as financial adviser and Nordic Issuing AB acts as the issuing agent in the rights issue.